Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?

CONCLUSION: Overall survival is improved when receiving autologous hematopoietic stem-cell transplantation as up-front therapy at first relapse in transplant-eligible FL whose disease relapses within 24 months of first-line therapy. Data from our single center look promising, but the data need to be replicated with a larger sample size.
PMID: 33558203 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - February 5, 2021 Category: Cancer & Oncology Authors: Yahya A, Radhwi O, Sobh M, Huebsch L, MacDonald D Tags: Clin Lymphoma Myeloma Leuk Source Type: research